RITAZAREM CRF Completion Guidelines
|
|
- Isabella Rosamund Dorsey
- 6 years ago
- Views:
Transcription
1 RITAZAREM CRF Completion Guidelines 10 Sept 2013 Version 1.2 Author: Michelle Lewin RITAZAREM Trial Coordinator Tel: +44(0) Fax: +44(0) Version Date Changes June July 2013 Renaming of Infections (non- SAE) Form to Infections Form September 2013 PROMIS questionnaire used from Month 0 onwards, not from Screening RITAZAREM CRF Completion Guide, v1.2, dated 10_September_2013 Page 1 of 6
2 General Instructions Abbreviations: Case Report Form Completion Guidelines AE BSA BVAS/WG CDA CRF CCTU EQ5D FDA GCP IV NA NAD ND NK PGA PROMIS SAE SF-36 SUSAR adverse event body surface area Birmingham Vasculitis Activity Score for WG Combined damage assessment index case report form Cambridge Clinical Trials Unit EuroQol 5D Quality of Life Questionnaire Food and Drug Administration Good Clinical Practice Intravenous not applicable no abnormalities detected not done not known Physicians Global Assessment Patient Reported Outcomes Measurement Information System serious adverse event Short Form (36) Health Survey Suspected Unexpected Serious Adverse Reaction General guidance Always refer to the study protocol before completing forms. Please ensure that you are using the most-to-date version of the CRF. A comprehensive list can be found on the RITAZAREM trial website at: All text must be provided in English. CRFs should always be signed and dated by the person completing them, and that person should be listed on the RITAZAREM delegation of responsibilities log (located in the site file) as being authorised to complete CRFs. By signing the CRF you are confirming that the information is correct to the best of your knowledge. Ensure data entries are consistent with the source data (usually the patient s medical notes). All data recorded on the study forms will be verifiable in the source documents maintained by the clinical sites according to FDA and ICH Good Clinical Practice (GCP) guidelines. Once a CRF is completed, please ensure a copy is placed in the patient s trial file. This may be a photocopy or the original if the CRFs are faxed/scanned and ed to the coordinating data centre. Completed CRFs should be returned to the coordinating office in Cambridge within 2 weeks of completion. If it becomes apparent that an error has been made on the CRF, please send an amended copy to the CCTU with a cover note to highlight that this is an updated version from the one previously sent. Ensure a copy of the amended CRF is retained at site along with the copy of the original which was sent. If a patient fails to attend an appointment or if for some other reason a scheduled assessment is missed the CCTU must be informed so that we can make a note of this on our database. Always use black pen. Always write clearly ensuring that the entries are legible to others. RITAZAREM CRF Completion Guide, v1.2, dated 10_September_2013 Page 2 of 6
3 Avoid abbreviations and acronyms, unless they are standard medical abbreviations or known to be acceptable. Ensure that you complete the header information on each page consistently. Always fill in EVERY field on each CRF page (unless indicated otherwise). If a procedure was not done or not applicable, enter ND or NA where appropriate, or tick/check the not done box. Do not write outside of the designated boxes. Completely fill in each box using leading 0 if needed, e.g. To amend incorrect data on a CRF page: score through the error with a single line, write the correct data nearby, initial and date each correction, do not obscure the original entry (do not use correction fluid). Do not record incomplete dates (i.e. if you know the month and year, but not the day, record- NK/APR/05). Record dates in the requested format dd/mmm/yy (e.g. 13 MAY 12). Tick/check the box to indicate the units used for weight, height, lab results etc. If a medication was given for an infection or a serious adverse event, make sure it is documented as fully as possible. Some questions will require a code to be entered according to a key provided (e.g. the Concomitant Medications form). Please ensure that you read the key for each section and follow any further instructions provided. Some CRF pages, for example the Concomitant Medications form and the Infections form, may require more than one page to be completed, but the number of pages is unknown before CRF completion. In this case, digit boxes are provided in the notation page of, which should be completed to indicate how many pages were filled populated. Questionnaires (SF-36, EQ-5D, PROMIS) are completed by the study participant. Local language versions of the questionnaires are available. The only adverse events being collected for RITAZAREM are infections requiring treatment with intravenous (IV) or oral antimicrobial, antiviral or antifungal medication, or infections commonly understood as opportunistic. There is no general AE reporting form, only an Infection Form. There will be a copy of the SAE reporting form on the website, and the form includes a front sheet detailing completion instructions and reporting timeframes as well as definitions of SAEs. RITAZAREM CRF Completion Guide, v1.2, dated 10_September_2013 Page 3 of 6
4 CRF Title Eligibility Form Enrolment Form Baseline Medical History Form When CRFs need to be completed At screening, once the patient has given informed consent, before enrolment At screening, once the patient has given informed consent At screening, once the patient has given informed consent and has been deemed eligible for the study Check List Form At each visit (Screen, Month 0, 1.5, 3, 4, 8, 12, 16, 20, 24, 27, 30, 36, 42 and 48) Clinical Laboratory Tests Form At each visit (Screen, Month 0, 1.5, 3, 4, 8, 12, 16, 20, 24, 27, 30, 36, 42 and 48) Follow-Up Form At each visit after Month 0 BVAS/WG Form At visit Months 0, 1.5, 3, 4, 8, 12, 16, 20, 24, 27, 30, 36, 42 and 48 CDA Form At visit Month 0, 4, 12, 24, 36, and 48 EQ5D Form At visit Month 0, 4, 12, 24, 36, 42, and 48 SF-36 Form At visit Month 0, 4, 12, 24, 36, 42, and 48 PROMIS At every visit from month 0 to month 48 Concomitant Medications Form New form at each visit Randomisation Form At Randomisation (Month 4 ± 14 days) Treatment Form - Rituximab Week 1, 2, 3, 4 (Induction Phase); then, if patient randomised to rituximab arm, Months 4, 8, 12, 16 and 20 (Maintenance Phase). If a patient relapses and is treated for the relapse Relapse Form As needed Infections Form Each time a patient is diagnosed with an infection (infection is any episode requiring antimicrobial, antiviral or antifungal medication), and each time there is updated information on an infection, until the infection has resolved. To be reported within 15 days of the event. SAE Form Within 24 hours of becoming aware of an SAE/SUSAR (see SAE coversheet for details). Check the event for seriousness; if the event meets 1 of the 5 serious criteria listed on the SAE Form, determine the causality and expectedness then fill in the SAE form concluding the nature of the event and subsequent actions. Pregnancy Form When a patient on the study falls pregnant while on study medication, and when there is a pregnancy outcome** Withdrawal Form If a patient withdraws/is withdrawn from the trial End of Trial Form When a patient reaches the end of the trial* Death Form When a patient dies *common close-out will be when the last patient reaches 12 months follow up (36 months after entry into the trial). **the patient must have given consent for follow-up of the pregnancy outcome RITAZAREM CRF Completion Guide, v1.2, dated 10_September_2013 Page 4 of 6
5 Page Specific Instructions Header information- all pages Field Comments Consistency check Study ID 6 digit: first three are the site ID*, Correct format second three are patient study ID. For example, the first patient in Boston, USA will be US1-001 Participant Initials If 2 initials, use dash in the middle digit box Not blank, check consistency Date of Birth Use format dd/mmm/yy Not blank, check consistency Evaluation Date Use format dd/mmm/yy Not blank, check consistency *Site ID will be provided by the CCTU. BVAS/WG There is a separate BVAS/WG form for each assessment point; please ensure you use the correct form for the assessment. BVAS/WG is designed to capture clinical features that are directly due to active disease. In addition, the instrument separates the features that represent new or worse disease activity from those that represent persistent activity. Only tick the Persistent box only if the abnormality is persistent disease activity since the last assessment and not worse within the previous 28 days. Only tick the New/Worse box tick box if the abnormality since the last assessment is newly present or worse within the previous 28 days. When scoring BVAS/WG, it is important not to confuse activity with damage. Damage, defined as the presence of non-healing scars, is a concept distinct from current disease activity. Please remember to complete the Physician s Global Assessment (PGA) at the end of the BVAS/WG form. Clinical Laboratory Form Laboratory test results are permitted to be within ± 2 weeks of the date of the study evaluation. Concomitant Medications Please note, the Concomitant Medications form is not a running log. A new form must be completed at each assessment point, even if there are no changes to concomitant medications. All on-going concomitant medications must be documented on a new CRF page at each assessment. Please record only prescribed medications; it is not necessary to list vitamins and other dietary supplements. If more than one page is needed at a study evaluation, please complete multiple pages and populate the page number at the footer of the form. Eligibility Review Form All questions must be answered on the eligibility review. For a patient to be eligible, all inclusion criteria questions must be answered yes and all the exclusion criteria questions must be answered no. End of Trial Form The End of Trial is when a patient has completed 24 months follow-up (on study for 48 months), or when the last patient reaches 12 months follow-up (36 months after entry into the trial) and common close-out occurs. All patients must have this form completed unless they die during the trial period or if they withdraw consent. Enrolment Form RITAZAREM CRF Completion Guide, v1.2, dated 10_September_2013 Page 5 of 6
6 Enter the patient s height, weight, predniso(lo)ne regimen, ANCA and relapse type on the form. Log into the enrolment/randomisation system at and enter the required information. The system will calculate and output the Body Surface Area (BSA) and the induction dose of rituximab (mg/infusion), and provide the target randomisation date. The study ID of the patient will also be generated at this stage. Enter these data on the enrolment CRF. Infection Form A new infection form must be completed for every infection, even if concurrent with another infection. If more than one page is needed at a study evaluation, please complete multiple pages and populate the page number at the footer of the form. If an infection is on-going, please leave the date of resolution blank. When new information on an infection is available (or if the infection resolves), please submit a new form containing the new information, ticking the box to indicate this is further information on a previously-reported event. Please do not update an original, previously submitted CRF page. If the infection meets any of the definitions of an SAE, i.e. results in death, is life-threatening, requires hospitalisation or prolongs hospitalisation, results in persistent disability or incapacity, or consists of a congenital anomaly or birth defect, then an SAE form must be completed in addition to the infection form. Please note:saes must be reported within 24 hours of becoming aware of the event. Randomisation Form This should be completed at Month 4 ± 14 days. Enter the patients current predniso(lo)ne dose and BVAS/WG score. Log into the randomisation system at and enter the required information. The system will provide the treatment assignment. Enter these data on the randomisation CRF. Relapse Form The date of relapse for the purpose of this study is the date that symptoms necessitated a treatment change. This does not have to be the evaluation date on the relapse form, as relapse can occur between study visits. Please provide an answer to all the questions, even if you have answered yes to major relapse. Relapsed patients (first major or second minor relapse) leave protocolised treatment but remain on protocol for follow-up, i.e. they continue to follow the schedule of assessments for follow-up purposes. Serious Adverse Event (SAE) Form Please refer to the cover sheet of the SAE form for definitions, reporting timelines and where to send SAE forms. The trial details of study title, R&D number and EudraCT number will all be pre-populated on the form. You should complete the patient s initials, date of birth and subject ID. Please indicate if this is an initial or follow up report, and complete your centre number (the first three digits of the subject ID), as well as the remaining details. Treatment Form The treatment form should be used to record all the details concerning rituximab infusions, for both the induction and maintenance phases. Please complete a new form each time an infusion is given. The infusion number should be circled on the form. Any deviations from the infusion protocol should be detailed on the form. Withdrawal Form For the purposes of this study, withdrawal is withdrawal of protocolised treatment and not withdrawal of protocolised follow-up. All patients must continue to be followed up for safety purposes unless consent has been withdrawn. RITAZAREM CRF Completion Guide, v1.2, dated 10_September_2013 Page 6 of 6
I2S2 TRAINING Good Clinical Practice tips. Deirdre Thom Neonatal Nurse Coordinator
I2S2 TRAINING Good Clinical Practice tips Deirdre Thom Neonatal Nurse Coordinator Content Principal investigator (slides 3-5) Delegation and delegation log (slides 6-7) Informed consent (slides 8-15) Data
More informationDetails: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure
Details: Author: Razwan Mahroof - QA Clinical Trials Monitor SOP Pages: 10 Version No. of replaced SOP: 1.0 Effective date of replaced SOP: 04 December 2015 Approval: Version No: of the SOP being approved.
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM 003 SOP category: Trial Management Version number: 03 Version date:
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM-003 SOP category: Trial Management Version number: 04 Version date:
More informationM. Rickard, Research Governance and GCP Manager R. Fay Research Governance and GCP Manager Elizabeth Clough, Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance and Safety Reporting for Sponsored non-ctimps SOP Number: 26b Version 2.0 Number: Effective Date: 29th November 2015 Review Date: 3 rd December
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationStandard Operating Procedure
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-07-004 Recording, managing and reporting Adverse Events for Clinical Trials of Investigational Medicinal Products and trials of Advanced
More informationAdverse Event Reporting
Adverse Event Reporting The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.thh.nhs.uk/departments/research/research.htm
More informationSTANDARD OPERATING PROCEDURE SOP 205
STANDARD OPERATING PROCEDURE SOP 205 Adverse Events: Identifying, Recording and Reporting for CTIMPs Sponsored by the Norfolk and Norwich University Hospital NHS Foundation Trust Version 2.3 Version date
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Adverse Event Identification, Recording and Reporting in Clinical Trials of Investigational Medicinal SOP-RES-019 Version Number 2 Issue Date 08 th Dec
More informationIDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES
IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES DOCUMENT NO.: CR012 v2.0 AUTHOR: Raymond French ISSUE DATE: 18 September 2017 EFFECTIVE DATE: 02 October
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationVersion Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13
CONTROLLED DOCUMENT Reporting Research Incidents and Breaches Policy CATEGORY: CLASSIFICATION: PURPOSE Controlled Number: Document Policy Governance To set out the framework and principles for reporting
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title Safety Reporting and Pharmacovigilance SOP Index Number SOP 20 Version 4.0 Approval Date 31-Jan-2017 Effective Date 14-Feb-2017
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationResearch Adverse Event and Safety Reporting Procedures Outcome Statement: Title:
Title: Research Adverse Event and Safety Reporting Procedures Outcome Statement: Research Teams will be able to correctly identify and report Adverse Events and complete Annual Safety Reports for research
More informationCOATS Coordinating Center Memo #3
TO: COATS Study Coordinators FROM: Kimberly Ring Data Coordinating Center DATE: March 25, 2009 RE: SAE QxQ COATS Coordinating Center Memo #3 This memo addresses the COATS SAE QxQ, which is now available.
More informationReference Number: UHB 253 Version Number: 1 Date of Next Review: 22/01/2018 Previous Trust/LHB Reference Number: SR-RG-015
Reference Number: UHB 253 Version Number: 1 Date of Next Review: 22/01/2018 Previous Trust/LHB Reference Number: SR-RG-015 Safety Reporting in CTIMPs Standard Operating Procedure Introduction and Aim The
More informationMarie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance processing for the JRMO SOP Number: 26c Version Number: V1 Effective Date: 5/8/16 Review Date: 5/8/17 Author: Reviewer: Reviewer: Authorisation:
More informationFERCI MODEL SOPs. [The IEC members (author/s, reviewer/s) and Chairperson will sign and date the SOP on this first page]
Title: SOP Code: SOP 12/V1 [The IEC members (author/s, reviewer/s) and Chairperson will sign and date the SOP on this first page] Prepared by: Dr. Padmaja Marathe, FERCI Member (Signature with Date) Reviewed
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationSafety Reporting in Clinical Research Policy Final Version 4.0
Safety Reporting in Clinical Research Policy Final Version 4.0 Category: Summary: Equality Assessment undertaken: Impact Policy The Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting
Study Management SM 306.00 STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick M. Schnell, MD,
More informationVersion 4 January 18, Principal Investigator: James F. Marion, M.D. The Mount Sinai School of Medicine
Guidelines for Completing Case Report Forms For A Six-Week Randomized Double-Blind, Controlled Trial of High Dose Asacol (6.0 g/day) Versus Low Dose Asacol (2.4 or 3.6 g/day) for the Treatment of Mild
More informationBiomedical IRB MS #
Department for Human Research Protections Institutional Review Boards Biomedical IRB MS # 1035 419-383-6796 IRB.Biomed@utoledo.edu Social, Behavioral and Educational IRB MS # 944 419-530-6167 IRB.SBE@utoledo.edu
More informationPOLICY ON RESEARCH RELATED ADVERSE EVENT REPORTING
POLICY ON RESEARCH RELATED ADVERSE EVENT REPORTING CLASSIFICATION TRUST POLICY NUMBER APPROVING COMMITTEE R & D Governance Committee RATIFYING COMMITTEE Quality & Risk Committee DATE RATIFIED October 2009
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationChecklist prior to recruiting first patient
Pre-Site selection Site Initiation Visit (SIV) What kind of questions should you ask How you should prepare for this visit Delegation logs Training logs ECRF/CRF Checklist prior to recruiting first patient
More informationPROMPTLY REPORTABLE EVENTS
PROMPTLY REPORTABLE EVENTS PURPOSE AND SCOPE To define the structure and responsibility for reporting unanticipated problems that occurs during the conduct of research. APPLICABLE REGULATIONS Policy II.02
More informationStandard Operating Procedure (SOP)
Standard Operating Procedure MANAGEMENT OF BREACHES IN RESEARCH SETTING AUDIENCE ISSUE Trustwide for research sponsored by UHBristol All research staff involved in UH Bristol sponsored research This SOP
More informationVCU Clinical Research Quality Assurance Assessment
VCU Clinical Research Quality Assurance Assessment Principal Investigator Protocol Title Protocol IRB Number Name of Person Completing Assessment Date Assessment was Completed The goal of this assessment
More informationSOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY. Contact Jess Bisset, Research Operations Manager x20227
SOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY SETTING FOR STAFF QUERIES Trust wide All staff involved in research Contact Jess Bisset, Research Operations Manager x20227 Guidance 1. Introduction In accordance
More informationStudy Guide for Emergency Care Clinicians. (Version /09/2014)
Study Guide for Emergency Care Clinicians (Version 1.2 26/09/2014) Notes 1. These learning materials are aimed primarily at paramedics, ambulance nurses, emergency care practitioners and doctors recruiting
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording, Managing and Reporting Adverse Events SOP Number: 2 Version Number: 3.0 Supersedes: 2.1 Effective date: May 2013
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Delegated Responsibilities in Research Projects SOP Number: 11 Version Number: 2.0 Supercedes: 1.0 Effective date: August
More information11/18/2016. UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities SESSION 4
UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016
More informationDCP Safety Committee. Update and Review. January 19, 2017
DCP Safety Committee Update and Review January 19, 2017 1 Overview: FDA s IND Safety Final Rule DCP s Response DCP Safety Committee Harmonizing Medical Monitors Process SAE Reporting SAE Flow Chart Process
More information2017/2018 Prostate Cancer Innovation Fund Terms of Reference
2017/2018 Prostate Cancer Innovation Fund Terms of Reference I. Table of Contents II. Background... 2 III. Key Dates... 2 IV. Objectives and Scope... 2 V. Eligibility... 3 A. Eligible Applicants... 3 B.
More informationSite Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG
Site Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG INFORMATION AND GUIDANCE SHEET FOR THE COMPLETION OF THE SITE SIGNATURE AND
More informationHuman Research Ethics Review Policy
Policy Document Title: Document ID: Document Name: Human Research Ethics Review Policy PY-RSH-300305 Human Research Ethics Review Policy Version Number: 2 Revision Date: Key Words 28/10/2014 10:54:00 AM
More informationNew European Union Clinical Trial Regulations
New European Union Clinical Trial Regulations Incorporate Monitoring and Safety Reporting Techniques into U.S. and EU Clinical Trial SOPs Anita K. Murthy Deputy Director, Global Regulatory Affairs Bayer
More informationRegistry eform Data Entry Guidelines Version Apr 2014 Updated for eform on 20 Jun 2016
Registry eform Data Entry Guidelines Version 1.0 02 Apr 2014 Updated for eform on 20 Jun 2016 Part 3 General recommendation for data entry in ProMISe and instructions of completion for the Follow up Form
More informationACRIN ADVERSE EVENT REPORTING MANUAL. 1 March 2006 v.3
AMERICAN COLLEGE OF RADIOLOGY IMAGING NETWORK ADVERSE EVENT REPORTING MANUAL 1 Prepared by the American College of Radiology Imaging Network Administrative Center September 2002 Revised March 2006 American
More informationMANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS DOCUMENT NO.: CR010 v4.0 AUTHOR: Heather Charles ISSUE DATE: 01 September 2016 EFFECTIVE DATE: 15 September 2016 1 INTRODUCTION 1.1 The Academic
More informationDrugs and Cosmetics rules, 2013 India
Drugs and Cosmetics rules, 2013 India Dr.Pankaj Shah Professor, Dept of Community Medicine, SRMC & RI, & Member Secretary, IEC II, SRU, Chennai Three important amendments 30 th Jan 2013 1 St Feb 2013 8
More informationACTIONS/PSOP/001 Version 1.0 Page 2 of 6
1. The purpose of the Pharmacy Site File To enable the designated trust pharmacy to fulfil its role and exercise appropriate control over all aspects of study medication handling, an accurately maintained
More informationOverview of Draft Pharmacovigilance Protocol
Overview of Draft Pharmacovigilance Protocol Identifying ADRs in Africa Special Challenges Malaria - pan-systemic clinical features Life-threatening condition Real-world trial AS/SP and co-artem safety
More informationDrugs and Cosmetics (First Amendment) Rules, 2013
Ministry : Ministry of Health and Family Welfare Department/Board : Health Notification No. : GSR53(E) Date of Notification : 30.01.2013 Drugs and Cosmetics (First Amendment) Rules, 2013 G.S.R.53(E).--Whereas
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording and Reporting Deviations, Violations, Potential Serious Breaches, Serious Breaches and Urgent Safety Measures
More informationEuropean Medicines Agency Inspections ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS
European Medicines Agency Inspections London, 23 July 2008 EMEA/INS/GCP/197215/2005 Procedure no.: INS/GCP/3/V ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS GCP
More informationStandard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research
Standard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research For Completion by SOP Author Reference Number PHT/RDSOP/002 Version V2.0 07 Apr 2016 Document Author(s) Document Reviewer(s)
More informationGCP: Investigator Responsibilities. Susan Tebbs Nicola Kaganson
GCP: Investigator Responsibilities Susan Tebbs Nicola Kaganson Investigator Responsibilities Qualifications & agreements Resources Responsibilities to the subject Ethics The protocol The IMP & randomisation
More informationA Screen patients G Review/Accountability/Sign off Form 2:Dosing Log M IMP Supply/Management. SAE clinical review/causality Assessment and Sign off
Site Delegation Log Study Name: Hospital: ELFIN EudraCT No: 2012-004260-22 REC Reference: 13/EM/0118 Title: Investigator: A multi-centre randomised placebo-controlled trial of prophylactic enteral lactoferrin
More informationSYSTEMS 2 (L160) A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma
SYSTEMS 2 (L160) A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma ISRCTN No: ISRCTN12698107 Protocol No: SYSTEMS 22015
More informationGuideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Adverse Event Reporting in Clinical Medical Device Trials SOP-RES-033 Version Number 1 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review
More informationInitially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009 1:51 PM Approval By student13 student13 on 11/24/2009 1:52 PM Attendees
Location: Los Angeles Research Institute: Los Angeles, CA Investigation Product/Test Article: Laftr Visit Mechanism: On-site Initially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009
More informationAdverse Event Reporting
Adverse Event Reporting Clinical S.O.P. No.: 15 Compiled by: Approved by: Review date: November 2016 DOCUMENT HISTORY Version Detail of purpose / change Author / edited Date edited number by 1.0 New SOP
More informationMHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager
MHRA Findings Dissemination Joint Office Launch Jan. 2012 Presented by: Carolyn Maloney UHL R&D Manager Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection
More informationSOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationCLOSE OUT VISIT REPORT (NO CRF TO MONITOR)
Date: Page: 1 of 8 CLOSE OUT VISIT REPORT (NO CRF TO MONITOR) Protocol: PI Name: PI Address: Date of Visit: Monitor(s): Other Sponsor Personnel Present: Site Personnel Present at Visit (include names and
More informationBuilding Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies
Building Quality into Clinical Trials Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies Objectives Identify strategies for developing a Quality Management
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL REPORTING ADVERSE DRUG REACTIONS IN SOUTH AFRICA IMPORTANT NOTE This guideline applies only to the reporting of SAEs during clinical trials. An update of the guideline for this
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationClinical Trial Quality Assurance Common Findings
Clinical Trial Quality Assurance Common Findings Objectives Identify common findings found in research study reviews conducted by the CTQA Program Understand what findings require an action plan vs. a
More informationONADE s Data Quality Review
ONADE s Data Quality Review Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulatory Affairs in Animal Health Seminar Kansas State University Olathe March 06, 2018 Presenter: Ana
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationResearch Staff Training
REFERENCE: VERSION NUMBER: 3.0 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Research Infrastructure Manager REVIEWED BY: Research & Innovation Group APPROVED BY: Deputy Director of Research CONTROLLER:
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationCANADIAN UROLOGICAL ASSOCIATION SCHOLARSHIP FUND BLADDER CANCER CANADA RESEARCH GRANT. Terms of Reference Background
CANADIAN UROLOGICAL ASSOCIATION SCHOLARSHIP FUND BLADDER CANCER CANADA RESEARCH GRANT Terms of Reference 2017-18 Background The CUASF-BCC Research Competition was initiated by Bladder Cancer Canada (BCC)
More informationUniversity of South Carolina. Unanticipated Problems and Adverse Events Guidelines
University of South Carolina Unanticipated Problems and Adverse Events Guidelines These guidelines define the procedures of USC for addressing unanticipated problems involving risks to research participants
More informationQUALITY ASSURANCE PROGRAM
QUALITY ASSURANCE PROGRAM Elaine Armstrong, MS Quality Assurance Manager PURPOSE Verify accuracy of submitted data Verify compliance with protocol and regulatory requirements Provide educational support
More informationEMA Inspection Site perspective
EMA Inspection Site perspective Hermien Gous Wits RHI Shandukani Research Centre 27.09.2016 Cape Town Why were we inspected times? Pharmaceutical company applied for registration of the study drug in a
More information3 HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION
1 PURPOSE The purpose of this procedure is to describe the method by which Adverse Events (AE)/relevant Safety Information and Product Quality Complaints (PQC) will be received, triaged, and documented
More informationKBEMS Pilot Programs- Adverse Event Notification
KBEMS Pilot Programs- Adverse Event tification Emergencies and Reporting of Adverse Events The responsible project coordinator must promptly notify the Kentucky Board of EMS & the KCTCS HSRB of any problems
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Urgent Safety Measures SOP-RES-022 Version Number 1 Issue Date 30 th April 2014 Effective Date 28 th May 2014 Review Date 28 th May 2016 Author(s) Reviewer(s)
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationSOP19a & 19b: Standard Operating Procedure for (a) Safety Monitoring (especially Pharmacovigilance) & (b) Urgent Safety Measures
SOP19a & 19b: Standard Operating Procedure for (a) Safety Monitoring (especially Pharmacovigilance) & (b) Urgent Safety Measures Authorship Team: Anne Seagrove, Melanie Storey, Ian Russell for Joint SOP
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationThe Clinical Research Center Research Practice Manual. Guideline for Study Document and Data Handling RPG-08. Guideline. Purpose.
The Clinical Research Center Research Practice Manual Guideline for Study Document and Data Handling RPG-08 Purpose Guideline This Guideline provides functional definitions for common data management terms;
More informationDocument Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator
including Roles and Responsibilities for the Conduct of Research Studies and Clinical Trials including CTIMPs (Clinical Trials of Investigational Medicinal Products) Document Number: 006 Version: 1 Ratified
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationHuman Research Governance Review Policy
Policy Document Title: Document ID: Document Name: Human Research Governance Review Policy PY-RSH-300304 Human Research Governance Review Policy Version Number: 2 Revision Date: Key Words 28/10/2014 10:40:00
More informationThe GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationAN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES
1 AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES Key Clinical Study Tasks and Activities 2 Discussion of Key Tasks and Activities 3 Development of the Clinical Protocol and Study Materials 3 Qualification
More informationPFF Patient Registry Protocol Version 1.0 date 21 Jan 2016
PFF Patient Registry Protocol Version 1.0 date 21 Jan 2016 Contents SYNOPSIS...3 Background...4 Significance...4 OBJECTIVES & SPECIFIC AIMS...5 Objective...5 Specific Aims... 5 RESEARCH DESIGN AND METHODS...6
More informationSite Closedown Checklist for UoL Sponsored CTIMP Studies
Site Closedown Checklist for UoL Sponsored CTIMP Studies Site Information Site: Study Title: UoL study number: Centre name: Investigator: Date of Visit: Date of Report Date Responses due by: List of site
More informationSerious Adverse Events
The REDOXS Study REducing Deaths due to OXidative Stress A randomized trial of glutamine and antioxidant supplementation in critically ill patients Serious Adverse Events This study is registered at Clinicaltrials.gov.
More informationClinical Documentation
Approved by: Chief Operating Officer; and Chief Medical Officer Clinical Documentation Corporate Policy & Procedures Manual Number: III-120 Date Approved January 4, 2018 Date Effective February 9, 2018
More informationI. Scope This policy defines unanticipated problems and adverse events and establishes the reporting process and timeline.
Human Research Protection Program Policies & Procedures Unanticipated Problems and Adverse Events Version 3.0 Date Effective: 11.9.2012 Research Integrity Office Mail code L106-RI Portland, Oregon 97239-3098
More informationAdopting Standardized Definitions The Future of Data Collection and Benchmarking in Alternate Site Infusion Must Start Now!
Adopting Standardized Definitions The Future of Data Collection and Benchmarking in Alternate Site Infusion Must Start Now! Connie Sullivan, RPh Infusion Director, Heartland IV Care Lyons, CO CE Credit
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationMedical Device Reporting. FD&C Act CFR Direct Final Rule 2/28/05. As amended by:
Medical Device Reporting Direct Final Rule 2/28/05 FD&C Act 519 As amended by: Safe Medical Devices Act of 1990 Medical Device Amendments of 1992 FDA Modernization Act of 1997 Authority to require manufacturers,
More informationHertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust
Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust STANDARD OPERATING PROCEDURE FOR RESEARCH Definition of Responsibilities for Externally
More information